Physician profile
Mary Denius
NPI 1427349273
$13,601.76
in general payments reported to CMS, 2019-2025
59 companies · $2,487 in 2025
The $2,487 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,590 · 2022: $2,614 · 2023: $2,688 · 2024: $3,223 · 2025: $2,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,615 · Long Term Medical Supply Or Device Loan: $583 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,614.69 |
| Long Term Medical Supply Or Device Loan | $583.31 |
| Education | $199.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,899.36 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $1,040.67 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $884.29 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Daiichi Sankyo INC. | $665.01 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Exelixis INC. | $661.85 | 2021-2025 | Cabometyx |
| Eisai INC. | $503.64 | 2021-2025 | |
| Incyte Corporation | $502.53 | 2021-2025 | Monjuvi, Jakafi |
| Lilly USA, LLC | $417.00 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals Lp | $391.90 | 2021-2025 | Calquence, Lynparza, Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $368.18 | 2021-2025 | |
| Gilead Sciences, INC. | $336.95 | 2023-2025 | Trodelvy |
| Celgene Corporation | $300.30 | 2021-2025 | Reblozyl, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $280.26 | 2021-2025 | Alunbrig, Ninlaro, Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $261.26 | 2021-2025 | Opdivo |
| Tersera Therapeutics LLC | $247.05 | 2021-2025 | Xermelo, Zoladex |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $235.04 | 2021-2024 | |
| Aveo Pharmaceuticals, INC. | $227.00 | 2022-2025 | |
| Pfizer INC. | $206.36 | 2021-2025 | |
| Emd Serono, INC. | $205.21 | 2021-2025 | Bavencio |
| Pharmaessentia USA Corporation | $200.72 | 2023-2025 | Besremi |
| Abbvie INC. | $191.53 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $154.09 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Glaxosmithkline, LLC. | $153.67 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Stemline Therapeutics INC. | $146.46 | 2023-2025 | Orserdu |
| Seagen INC. | $142.48 | 2021-2023 | Adcetris, Tukysa |
| Amgen INC. | $124.78 | 2021-2023 | Blincyto, Kyprolis |
| Karyopharm Therapeutics INC. | $119.65 | 2021-2024 | Xpovio |
| Beigene USA, INC. | $117.77 | 2021-2024 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $103.69 | 2021-2025 | Onivyde, Somatuline Depot |
| Genentech USA, INC. | $101.60 | 2022-2025 | Polivy, Tecentriq, Phesgo |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Alexion Pharmaceuticals, INC. | $96.25 | 2021-2025 | Ultomiris |
| Array Biopharma INC | $91.58 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Puma Biotechnology, INC. | $91.54 | 2021-2025 | |
| Astellas Pharma US INC | $88.84 | 2023-2025 | Xospata, Vyloy |
| Pharmacyclics LLC, An Abbvie Company | $80.93 | 2021-2022 | |
| Syndax Pharmaceuticals, INC. | $67.87 | 2025 | |
| Adc Therapeutics America, INC. | $66.09 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $64.16 | 2021-2025 | Libtayo |
| Morphosys, US INC. | $63.35 | 2021-2023 | Monjuvi |
| G1 Therapeutics, INC. | $62.43 | 2022-2023 | Cosela |
| Pharmacosmos Therapeutics INC. | $62.35 | 2021-2024 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.60 | 2024-2025 | Gilotrif |
| Acceleron Pharma, INC. | $49.57 | 2021 | |
| Myovant Sciences INC. | $48.53 | 2021-2022 | |
| Beone Medicines USA, INC. | $34.71 | 2025 | Brukinsa |
| Taiho Oncology, INC. | $31.71 | 2023-2024 | |
| Mirati Therapeutics, INC. | $31.38 | 2023-2024 | Krazati |
| Blueprint Medicines Corporation | $28.91 | 2021 | |
| Sobi, INC | $28.72 | 2023 | |
| Dova Pharmaceuticals | $28.55 | 2021 | |
| Deciphera Pharmaceuticals INC. | $20.53 | 2024 | Qinlock |
| Caris Mpi, INC. | $20.06 | 2025 | Mi Cancer Seek |
| Recordati_rare_diseases_inc. | $19.66 | 2024 | Sylvant |
| Alnylam Pharmaceuticals INC. | $18.54 | 2023 | Givlaari |
| Adaptive Biotechnologies Corporation | $17.00 | 2024 | Clonoseq |
| Spectrum Pharmaceuticals INC. | $14.13 | 2024 | Rolvedon |
| Medtronic, INC. | $13.01 | 2023 | Osteocool Rf Ablation System |
| Secura Bio, INC. | $9.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Denius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.